SYGNIS AG

EANS-Adhoc: SYGNIS Pharma AG
SYGNIS announces the adaptation of its organisation to the new business activity

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Strategic management decisions/Company Information
20.12.2012


Ad hoc-Release according to § 15 WpHG
      
SYGNIS announces the adaptation of its organisation to the new business activity

Heidelberg 20 December 2012 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard) announced today the discontinuation of its
therapeutic R&D project KIBRA and the adaptation of its organisation to the new
business activity. At the Heidelberg site the staff will be reduced by 10
employees. These measures are implemented to concentrate the financial resources
on the development and marketing of novel technologies in molecular biology in
line with the new corporate strategy. This new business was acquired in 2012 by
joining forces with the Spanish 
X-Pol Biotech.
Relating to the reduction of staff, the Company expects a one-time total expense
of up to EUR 0.2 million. In addition non-cash related impairments with regard
to intangible assets of up to EUR 3.2 million could occur.
**** end of ad hoc ****


For further information please contact:


SYGNIS Pharma AG                        
Peter Willinger
CFO                     

Tel: +49 6221 454 836                   
Email: willinger@sygnis.de
                


### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from
the established conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these statements in the
light of new information or future results or for any other reason.
###


Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:     contact@sygnis.de
WWW:      http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1RFM03
indexes:     
stockmarkets: 
language:   English
 



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: